TKI Landscape for Ph+ ALL Expanding

被引：0
|
作者：
Pob, Alissa
机构：
来源：
CANCER DISCOVERY | 2023年 / 13卷 / 04期
关键词：
D O I：
10.1158/2159-8290.CD-NB2023-0011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Identification of FoxM1 As Therapeutic Target in TKI-Resistant Ph+ ALL
    Buchner, Maike
    Klemm, Lars
    Chen Zhengshan
    Geng, Huimin
    Muschen, Markus
    BLOOD, 2012, 120 (21)
  • [2] Asciminib for Ph+ ALL: a forward?
    Lang, Fabian
    Ottmann, Oliver G.
    BLOOD, 2025, 145 (06) : 551 - 552
  • [3] ARF way to Ph+ ALL stratification?
    Fielding, Adele K.
    BLOOD, 2018, 131 (13) : 1394 - +
  • [4] MOLECULAR HETEROGENEITY OF ADULT PH+ ALL
    LEIBOWITZ, D
    SCHAEFERREGO, K
    ARLIN, Z
    SHAPIRO, L
    MEARS, JG
    BANK, A
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1987, : 195 - 195
  • [5] Hyper-CVADinib for Ph+ ALL
    Weiss, MA
    BLOOD, 2004, 103 (12) : 4377 - 4377
  • [6] Ph+ ALL in 2022: is there an optimal approach?
    Wieduwilt, Matthew J.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2022, (01) : 206 - 212
  • [7] A challenging choice : consolidation in Ph+ ALL
    Luskin, Marlise R.
    BLOOD, 2022, 140 (20) : 2093 - 2094
  • [8] Ponatinib superior to imatinib in Ph+ ALL
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (07) : 483 - 483
  • [9] Emergence of a Ph-negative Clone in a Child With Ph+ ALL
    Mehrhoff, Casey J.
    Hemenway, Charles S.
    Suh, Eugene
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2020, 42 (06) : E466 - E468
  • [10] Ph+ ALL:: another success for imatinib -: Comment
    Maziarz, RT
    BLOOD, 2005, 105 (09) : 3388 - 3389
12345